Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 3:30 p.m. PST on Wednesday, January 13, 2010, at the J.P. Morgan 28th Annual Healthcare Conference in San Francisco.

The presentation will include updates on Geron’s telomerase inhibitor drug (imetelstat sodium - GRN163L) and telomerase therapeutic vaccine (GRNVAC1) as well as the company’s human embryonic stem cell development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1), diabetes (GRNIC1), and osteoarthritis (GRNCHND1).

The webcast link for the live audio and slide presentation will be available on the Events page in the Investors section of Geron’s website at http://www.geron.com/investors/factsheet/events.aspx. The presentation will be archived for replay shortly after the live event and available for 30 days.

About Geron

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers. For more information, visit www.geron.com.